Ali I Fattom

Summary

Publications

  1. ncbi Antigenic determinants of Staphylococcus aureus type 5 and type 8 capsular polysaccharide vaccines
    A I Fattom
    W W Karakawa Microbial Pathogenesis Laboratory, NABI, Rockville, MD 20852, USA
    Infect Immun 66:4588-92. 1998
  2. ncbi Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials
    Ali I Fattom
    Nabi Biopharmaceuticals, 12280 Wilkins Avenue, Rockville, MD 20852, USA
    Vaccine 22:880-7. 2004
  3. ncbi Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients
    Ali Fattom
    WW Karakawa Microbial Pathogenesis Laboratory, Nabi Biopharmaceuticals, 12280 Wilkins Ave, Rockville, MD 20852, USA
    Vaccine 23:656-63. 2004
  4. ncbi Identification of the capsular polysaccharides in Staphylococcus aureus clinical isolates by PCR and agglutination tests
    Isabelle Verdier
    INSERM, E0230, Lyon, F 69008, France
    J Clin Microbiol 45:725-9. 2007
  5. ncbi Distribution of capsular and surface polysaccharide serotypes of Staphylococcus aureus
    Christof von Eiff
    Institute of Medical Microbiology, University Hospital of Munster, 48149 Munster, Germany
    Diagn Microbiol Infect Dis 58:297-302. 2007
  6. ncbi Serotyping of Dutch Staphylococcus aureus strains from carriage and infection
    Damian C Melles
    Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    FEMS Immunol Med Microbiol 52:287-92. 2008

Collaborators

Detail Information

Publications6

  1. ncbi Antigenic determinants of Staphylococcus aureus type 5 and type 8 capsular polysaccharide vaccines
    A I Fattom
    W W Karakawa Microbial Pathogenesis Laboratory, NABI, Rockville, MD 20852, USA
    Infect Immun 66:4588-92. 1998
    ..Moreover, the antibodies of different specificities (backbone or O-acetyl) are all functional and efficient against the variations in bacterial CP that may occur among clinically significant S. aureus pathogenic isolates...
  2. ncbi Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials
    Ali I Fattom
    Nabi Biopharmaceuticals, 12280 Wilkins Avenue, Rockville, MD 20852, USA
    Vaccine 22:880-7. 2004
    ..aureus bacteremia for up to 10 months following a single immunization. The history, epidemiology, serology, and development of StaphVAX, including preclinical and clinical studies demonstrating efficacy are described in this review...
  3. ncbi Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients
    Ali Fattom
    WW Karakawa Microbial Pathogenesis Laboratory, Nabi Biopharmaceuticals, 12280 Wilkins Ave, Rockville, MD 20852, USA
    Vaccine 23:656-63. 2004
    ..001). We conclude that a booster immunization to maintain protective levels of specific antibodies for an extended period of time is feasible for patients at continuous risk for S. aureus bacteremia...
  4. ncbi Identification of the capsular polysaccharides in Staphylococcus aureus clinical isolates by PCR and agglutination tests
    Isabelle Verdier
    INSERM, E0230, Lyon, F 69008, France
    J Clin Microbiol 45:725-9. 2007
    ..All S. aureus clinical isolates included in the present study have been investigated by PCR method, demonstrating that all isolates carried either the cap5 or the cap8 locus...
  5. ncbi Distribution of capsular and surface polysaccharide serotypes of Staphylococcus aureus
    Christof von Eiff
    Institute of Medical Microbiology, University Hospital of Munster, 48149 Munster, Germany
    Diagn Microbiol Infect Dis 58:297-302. 2007
    ....
  6. ncbi Serotyping of Dutch Staphylococcus aureus strains from carriage and infection
    Damian C Melles
    Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    FEMS Immunol Med Microbiol 52:287-92. 2008
    ..Thus, addition of the 336PS conjugate to a type 5- and type 8-CP protein conjugate vaccine would significantly extend the vaccine coverage...